Amryt Pharma plc

7.20-0.1600-2.17%Vol 192.45K1Y Perf -37.94%
Jun 24th, 2022 16:00 DELAYED
BID5.78 ASK8.93
Open7.54 Previous Close7.36
Pre-Market- After-Market7.28
 - -  0.08 1.11%
Target Price
22.40 
Analyst Rating
Strong Buy 1.00
Potential %
211.11 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
     41.54
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★★★+     55.11
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
20.28 
Earnings Rating
Market Cap461.80M 
Earnings Date
5th Aug 2022
Alpha0.00 Standard Deviation0.13
Beta0.51 

Today's Price Range

7.127.54

52W Range

5.6113.45

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
2.56%
1 Month
-7.10%
3 Months
-13.25%
6 Months
-29.41%
1 Year
-37.94%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
AMYT7.20-0.1600-2.17
AAPL141.663.39002.45
GOOG2 370.76117.07005.19
MSFT267.708.84003.41
XOM86.901.69001.98
WFC40.762.86007.55
JNJ182.292.63001.46
FB196.640.99000.51
GE67.083.01004.70
JPM117.323.40002.98
Financial StrengthValueIndustryS&P 500US Markets
1.00
1.90
0.37
0.60
0.40
Leverage Ratio 2.80
ProfitabilityValueIndustryS&P 500US Markets
51.20
4.70
28.10
-92.20
1.31
RevenueValueIndustryS&P 500US Markets
233.24M
3.64
100.09
197.73
Earnings HistoryEstimateReportedSurprise %
Q01 2022-0.05-0.050.00
Q04 2021-0.140.15207.14
Q03 2021-0.21-0.0766.67
Q02 2021-0.09-0.0455.56
Q01 2021--0.09-
Q03 2020--0.07-
Q02 2020--0.12-
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date5th Aug 2022
Estimated EPS Next Report-0.04
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume192.45K
Shares Outstanding64.14K
Shares Float0
Trades Count1.57K
Dollar Volume1.40M
Avg. Volume97.44K
Avg. Weekly Volume140.35K
Avg. Monthly Volume75.81K
Avg. Quarterly Volume76.15K

Amryt Pharma plc (NASDAQ: AMYT) stock closed at 7.2 per share at the end of the most recent trading day (a -2.17% change compared to the prior day closing price) with a volume of 192.45K shares and market capitalization of 461.80M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 88 people. Amryt Pharma plc CEO is Joseph Amrit Wiley.

The one-year performance of Amryt Pharma plc stock is -37.94%, while year-to-date (YTD) performance is -33.33%. AMYT stock has a five-year performance of %. Its 52-week range is between 5.61 and 13.45, which gives AMYT stock a 52-week price range ratio of 20.28%

Amryt Pharma plc currently has a PE ratio of 31.90, a price-to-book (PB) ratio of 1.30, a price-to-sale (PS) ratio of 1.93, a price to cashflow ratio of 75.40, a PEG ratio of 2.32, a ROA of 0.47%, a ROC of 4.77% and a ROE of 1.52%. The company’s profit margin is 1.31%, its EBITDA margin is 28.10%, and its revenue ttm is $233.24 Million , which makes it $3.64 revenue per share.

Of the last four earnings reports from Amryt Pharma plc, there were 3 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.04 for the next earnings report. Amryt Pharma plc’s next earnings report date is 05th Aug 2022.

The consensus rating of Wall Street analysts for Amryt Pharma plc is Strong Buy (1), with a target price of $22.4, which is +211.11% compared to the current price. The earnings rating for Amryt Pharma plc stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Amryt Pharma plc has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Amryt Pharma plc has a Sell technical analysis rating based on Technical Indicators (ADX : 45.14, ATR14 : 0.45, CCI20 : -38.04, Chaikin Money Flow : -0.01, MACD : -0.24, Money Flow Index : 61.73, ROC : -8.40, RSI : 43.62, STOCH (14,3) : 47.59, STOCH RSI : 0.79, UO : 42.47, Williams %R : -52.41), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Amryt Pharma plc in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
5 (100.00 %)
5 (100.00 %)
5 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Amryt Pharma plc

Amryt Pharma PLC is a specialty pharmaceutical company. It is focused on developing and delivering new treatments to help improve the lives of patients with rare or orphan diseases. It holds an exclusive license to sell Lojuxta (lomitapide) for adults, across the European Union and other territories including the Middle East, North Africa, Turkey and Israel. Lojuxta is used to treat a rare life-threatening disease called Homozygous Familial Hypercholesterolemia. Myalept (metreleptin) is an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients. It derives most of the revenue from the European Economic Area (EEA).

CEO: Joseph Amrit Wiley

Telephone: +44 2030267257

Address: 196 High Road, London N22 8HH, , GB

Number of employees: 88

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

60%40%

Bearish Bullish

60%40%

Bearish Bullish

63%37%

TipRanks News for AMYT

Fri, 06 May 2022 20:08 GMT Amryt Pharma (AMYT) Gets a Buy Rating from Maxim Group

- TipRanks. All rights reserved.

Mon, 25 Apr 2022 10:15 GMT Analysts Offer Insights on Healthcare Companies: Amryt Pharma (AMYT) and Otonomy (OTIC)

- TipRanks. All rights reserved.

News

Stocktwits